Phaseline

Companies › Eloxx Pharmaceuticals

Eloxx Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Other; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Elx-02
80S Ribosome modulator
RPSA, RPS27, RPS6, RPS2, RPS3Phase 2Alport Syndrome, X-LinkedJun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07523581Elx-02Phase 2Alport Syndrome, X-LinkedOtherJun 2027

From the company's SEC filings

Cash of $62m on 2026-06-30; operating cash outflow about $21m a year; runway about 36 months at that burn, to Jun 2029; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

RPSA (1) RPS27 (1) RPS6 (1) RPS2 (1) RPS3 (1)

Companies with the same targets

–

Companies built like this

QED Therapeutics, a BridgeBio company Healx Skingenix Sensory Cloud Shanghai Huilun Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.